CN111192634A - 用于处理基因组数据的方法 - Google Patents
用于处理基因组数据的方法 Download PDFInfo
- Publication number
- CN111192634A CN111192634A CN202010098891.4A CN202010098891A CN111192634A CN 111192634 A CN111192634 A CN 111192634A CN 202010098891 A CN202010098891 A CN 202010098891A CN 111192634 A CN111192634 A CN 111192634A
- Authority
- CN
- China
- Prior art keywords
- information
- subject
- genomic
- genomic sequence
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 118
- 238000012545 processing Methods 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 153
- 201000010099 disease Diseases 0.000 claims abstract description 102
- 230000002068 genetic effect Effects 0.000 claims abstract description 81
- 230000014509 gene expression Effects 0.000 claims abstract description 74
- 208000035475 disorder Diseases 0.000 claims abstract description 45
- 230000008569 process Effects 0.000 claims abstract description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 17
- 238000004891 communication Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 210000001519 tissue Anatomy 0.000 claims description 57
- 210000000056 organ Anatomy 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 34
- 238000012217 deletion Methods 0.000 claims description 25
- 230000037430 deletion Effects 0.000 claims description 25
- 230000001105 regulatory effect Effects 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000003780 insertion Methods 0.000 claims description 21
- 230000037431 insertion Effects 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 15
- 230000037361 pathway Effects 0.000 claims description 14
- 230000011987 methylation Effects 0.000 claims description 13
- 238000007069 methylation reaction Methods 0.000 claims description 13
- 230000008707 rearrangement Effects 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 108700024394 Exon Proteins 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 7
- 230000003426 interchromosomal effect Effects 0.000 claims description 7
- 238000012164 methylation sequencing Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 108020004485 Nonsense Codon Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 230000037434 nonsense mutation Effects 0.000 claims description 5
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 108091092195 Intron Proteins 0.000 claims description 4
- 108010026552 Proteome Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 claims description 3
- 108010033040 Histones Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 238000007481 next generation sequencing Methods 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- -1 promoters Proteins 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000002105 tongue Anatomy 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000005067 joint tissue Anatomy 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- 230000037442 genomic alteration Effects 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000008859 change Effects 0.000 description 31
- 206010061818 Disease progression Diseases 0.000 description 23
- 230000005750 disease progression Effects 0.000 description 23
- 238000012163 sequencing technique Methods 0.000 description 21
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 238000004422 calculation algorithm Methods 0.000 description 13
- 230000035772 mutation Effects 0.000 description 12
- 241000894007 species Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 231100000005 chromosome aberration Toxicity 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000012070 whole genome sequencing analysis Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 230000008238 biochemical pathway Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 208000035474 group of disease Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000012175 pyrosequencing Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000010386 affect regulation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000008711 chromosomal rearrangement Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003064 k means clustering Methods 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011840 criminal investigation Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434017P | 2011-01-19 | 2011-01-19 | |
| US61/434,017 | 2011-01-19 | ||
| CN2012800059273A CN103329138A (zh) | 2011-01-19 | 2012-01-19 | 用于处理基因组数据的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012800059273A Division CN103329138A (zh) | 2011-01-19 | 2012-01-19 | 用于处理基因组数据的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111192634A true CN111192634A (zh) | 2020-05-22 |
Family
ID=45607311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010098891.4A Pending CN111192634A (zh) | 2011-01-19 | 2012-01-19 | 用于处理基因组数据的方法 |
| CN2012800059273A Pending CN103329138A (zh) | 2011-01-19 | 2012-01-19 | 用于处理基因组数据的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012800059273A Pending CN103329138A (zh) | 2011-01-19 | 2012-01-19 | 用于处理基因组数据的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140229495A1 (https=) |
| EP (1) | EP2666115A1 (https=) |
| JP (1) | JP6420543B2 (https=) |
| CN (2) | CN111192634A (https=) |
| BR (1) | BR112013018139A8 (https=) |
| RU (1) | RU2013138422A (https=) |
| WO (1) | WO2012098515A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119541627A (zh) * | 2025-01-22 | 2025-02-28 | 温州医科大学附属眼视光医院 | 一种在基因转录水平评价蛋白质结合效率的方法、设备、介质和程序产品 |
| CN120496715A (zh) * | 2025-05-23 | 2025-08-15 | 康奥生物科技(天津)股份有限公司 | 一种试验遴选研究方法及系统 |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9773091B2 (en) | 2011-10-31 | 2017-09-26 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
| CN102841988B (zh) * | 2012-07-28 | 2015-10-21 | 盛司潼 | 一种对核酸序列信息进行匹配的系统和方法 |
| US9418203B2 (en) | 2013-03-15 | 2016-08-16 | Cypher Genomics, Inc. | Systems and methods for genomic variant annotation |
| WO2014149972A1 (en) | 2013-03-15 | 2014-09-25 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
| US11342048B2 (en) | 2013-03-15 | 2022-05-24 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
| US9898575B2 (en) | 2013-08-21 | 2018-02-20 | Seven Bridges Genomics Inc. | Methods and systems for aligning sequences |
| US9116866B2 (en) | 2013-08-21 | 2015-08-25 | Seven Bridges Genomics Inc. | Methods and systems for detecting sequence variants |
| WO2015027085A1 (en) | 2013-08-22 | 2015-02-26 | Genomoncology, Llc | Computer-based systems and methods for analyzing genomes based on discrete data structures corresponding to genetic variants therein |
| HK1226158A1 (zh) * | 2013-09-30 | 2017-09-22 | Seven Bridges Genomics Inc. | 用於检测序列变异体的方法和系统 |
| EP3495496B1 (en) | 2013-10-07 | 2020-11-25 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
| US20150106115A1 (en) * | 2013-10-10 | 2015-04-16 | International Business Machines Corporation | Densification of longitudinal emr for improved phenotyping |
| AU2014337093B2 (en) | 2013-10-18 | 2020-07-30 | Seven Bridges Genomics Inc. | Methods and systems for identifying disease-induced mutations |
| JP2017500004A (ja) | 2013-10-18 | 2017-01-05 | セブン ブリッジズ ジェノミクス インコーポレイテッド | 遺伝子試料について遺伝子型解析するための方法およびシステム |
| WO2015058095A1 (en) | 2013-10-18 | 2015-04-23 | Seven Bridges Genomics Inc. | Methods and systems for quantifying sequence alignment |
| US11049587B2 (en) | 2013-10-18 | 2021-06-29 | Seven Bridges Genomics Inc. | Methods and systems for aligning sequences in the presence of repeating elements |
| US9063914B2 (en) | 2013-10-21 | 2015-06-23 | Seven Bridges Genomics Inc. | Systems and methods for transcriptome analysis |
| EP3069285A4 (en) * | 2013-11-13 | 2017-08-30 | Five3 Genomics, LLC | Systems and methods for transmission and pre-processing of sequencing data |
| EP3092317B1 (en) | 2014-01-10 | 2021-04-21 | Seven Bridges Genomics Inc. | Systems and methods for use of known alleles in read mapping |
| US9817944B2 (en) | 2014-02-11 | 2017-11-14 | Seven Bridges Genomics Inc. | Systems and methods for analyzing sequence data |
| CN106537400B (zh) * | 2014-02-26 | 2019-04-09 | 南托米克斯公司 | 安全的移动基因组浏览设备及用于其的方法 |
| AU2015311677A1 (en) * | 2014-09-05 | 2017-04-27 | Nantomics, Llc | Systems and methods for determination of provenance |
| CA2964349C (en) | 2014-10-14 | 2023-03-21 | Seven Bridges Genomics Inc. | Systems and methods for smart tools in sequence pipelines |
| US10192026B2 (en) | 2015-03-05 | 2019-01-29 | Seven Bridges Genomics Inc. | Systems and methods for genomic pattern analysis |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| US10275567B2 (en) | 2015-05-22 | 2019-04-30 | Seven Bridges Genomics Inc. | Systems and methods for haplotyping |
| SG11201707649SA (en) * | 2015-06-24 | 2017-10-30 | Samsung Life Public Welfare Foundation | Method and device for analyzing gene |
| WO2017009402A1 (en) * | 2015-07-16 | 2017-01-19 | Koninklijke Philips N.V. | Device, system and method for managing treatment of an inflammatory autoimmune disease of a person |
| US10793895B2 (en) | 2015-08-24 | 2020-10-06 | Seven Bridges Genomics Inc. | Systems and methods for epigenetic analysis |
| US10584380B2 (en) | 2015-09-01 | 2020-03-10 | Seven Bridges Genomics Inc. | Systems and methods for mitochondrial analysis |
| US10724110B2 (en) | 2015-09-01 | 2020-07-28 | Seven Bridges Genomics Inc. | Systems and methods for analyzing viral nucleic acids |
| US11347704B2 (en) | 2015-10-16 | 2022-05-31 | Seven Bridges Genomics Inc. | Biological graph or sequence serialization |
| US20170199960A1 (en) | 2016-01-07 | 2017-07-13 | Seven Bridges Genomics Inc. | Systems and methods for adaptive local alignment for graph genomes |
| US10364468B2 (en) | 2016-01-13 | 2019-07-30 | Seven Bridges Genomics Inc. | Systems and methods for analyzing circulating tumor DNA |
| US10460829B2 (en) | 2016-01-26 | 2019-10-29 | Seven Bridges Genomics Inc. | Systems and methods for encoding genetic variation for a population |
| CA3014292A1 (en) | 2016-02-12 | 2017-08-17 | Regeneron Pharmaceuticals, Inc. | Methods and systems for detection of abnormal karyotypes |
| US10262102B2 (en) | 2016-02-24 | 2019-04-16 | Seven Bridges Genomics Inc. | Systems and methods for genotyping with graph reference |
| US10790044B2 (en) | 2016-05-19 | 2020-09-29 | Seven Bridges Genomics Inc. | Systems and methods for sequence encoding, storage, and compression |
| US10600499B2 (en) | 2016-07-13 | 2020-03-24 | Seven Bridges Genomics Inc. | Systems and methods for reconciling variants in sequence data relative to reference sequence data |
| US11289177B2 (en) | 2016-08-08 | 2022-03-29 | Seven Bridges Genomics, Inc. | Computer method and system of identifying genomic mutations using graph-based local assembly |
| US11250931B2 (en) | 2016-09-01 | 2022-02-15 | Seven Bridges Genomics Inc. | Systems and methods for detecting recombination |
| WO2018060365A1 (en) * | 2016-09-29 | 2018-04-05 | Koninklijke Philips N.V. | Genomic variant ranking system for clinical trial matching |
| SG11201903270RA (en) * | 2016-10-11 | 2019-05-30 | Genomsys Sa | Method and system for selective access of stored or transmitted bioinformatics data |
| US10319465B2 (en) | 2016-11-16 | 2019-06-11 | Seven Bridges Genomics Inc. | Systems and methods for aligning sequences to graph references |
| US11347844B2 (en) | 2017-03-01 | 2022-05-31 | Seven Bridges Genomics, Inc. | Data security in bioinformatic sequence analysis |
| US10726110B2 (en) | 2017-03-01 | 2020-07-28 | Seven Bridges Genomics, Inc. | Watermarking for data security in bioinformatic sequence analysis |
| EP3607481A1 (en) * | 2017-04-06 | 2020-02-12 | Koninklijke Philips N.V. | Method and apparatus for masking clinically irrelevant ancestry information in genetic data |
| US11177042B2 (en) * | 2017-08-23 | 2021-11-16 | International Business Machines Corporation | Genetic disease modeling |
| CN107609348B (zh) * | 2017-08-29 | 2020-06-23 | 上海三誉华夏基因科技有限公司 | 高通量转录组数据样本分类数目估计方法 |
| US20190156923A1 (en) * | 2017-11-17 | 2019-05-23 | LunaPBC | Personal, omic, and phenotype data community aggregation platform |
| CN107967410B (zh) * | 2017-11-27 | 2021-07-30 | 电子科技大学 | 一种面向基因表达与甲基化数据的融合方法 |
| CN107944224B (zh) * | 2017-12-06 | 2021-04-13 | 懿奈(上海)生物科技有限公司 | 构建皮肤相关基因标准型别数据库的方法及应用 |
| US12046325B2 (en) | 2018-02-14 | 2024-07-23 | Seven Bridges Genomics Inc. | System and method for sequence identification in reassembly variant calling |
| US11574701B1 (en) | 2018-11-28 | 2023-02-07 | Allscripts Software, Llc | Computing system for normalizing computer-readable genetic test results from numerous different sources |
| WO2020139379A1 (en) | 2018-12-28 | 2020-07-02 | LunaPBC | Community data aggregation, completion, correction, and use |
| CN109979537B (zh) * | 2019-03-15 | 2020-12-18 | 南京邮电大学 | 一种面向多条序列的基因序列数据压缩方法 |
| CN111028883B (zh) * | 2019-11-20 | 2023-07-18 | 广州达美智能科技有限公司 | 基于布尔代数的基因处理方法、装置及可读存储介质 |
| CN111785370B (zh) * | 2020-07-01 | 2024-05-17 | 医渡云（北京）技术有限公司 | 病历数据处理方法及装置、计算机存储介质、电子设备 |
| US20230260598A1 (en) * | 2022-02-14 | 2023-08-17 | AiOnco, Inc. | Approaches to normalizing genetic information derived by different types of extraction kits to be used for screening, diagnosing, and stratifying patients and systems for implementing the same |
| CN115602249B (zh) * | 2022-10-24 | 2025-12-30 | 哈尔滨工程大学 | 基于多视角图卷积网络的长链非编码rna-疾病关联预测系统 |
| WO2024186701A1 (en) * | 2023-03-03 | 2024-09-12 | AiOnco, Inc. | Algorithmic approach to removing extraction kit bias from genetic information and system for implementing the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009108802A2 (en) * | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440035A1 (en) * | 2001-03-05 | 2002-09-12 | Gene Logic, Inc. | A system and method for managing gene expression data |
| US7529685B2 (en) * | 2001-08-28 | 2009-05-05 | Md Datacor, Inc. | System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data |
| JP2003271735A (ja) * | 2002-03-12 | 2003-09-26 | Yokogawa Electric Corp | 遺伝子診断分析装置およびそれを用いた遺伝子診断支援システム |
| US7729865B2 (en) * | 2003-10-06 | 2010-06-01 | Cerner Innovation, Inc. | Computerized method and system for automated correlation of genetic test results |
| WO2006052242A1 (en) * | 2004-11-08 | 2006-05-18 | Seirad, Inc. | Methods and systems for compressing and comparing genomic data |
| US20060223058A1 (en) * | 2005-04-01 | 2006-10-05 | Perlegen Sciences, Inc. | In vitro association studies |
| CN101378764A (zh) * | 2005-12-09 | 2009-03-04 | 贝勒研究院 | 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测 |
| JP4852313B2 (ja) * | 2006-01-20 | 2012-01-11 | 富士通株式会社 | ゲノム解析プログラム、該プログラムを記録した記録媒体、ゲノム解析装置およびゲノム解析方法 |
| CA2688312A1 (en) * | 2007-05-25 | 2008-12-04 | Decode Genetics Ehf. | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
| JP2010157214A (ja) * | 2008-12-02 | 2010-07-15 | Sony Corp | 遺伝子クラスタリングプログラム、遺伝子クラスタリング方法及び遺伝子クラスター解析装置 |
-
2012
- 2012-01-19 CN CN202010098891.4A patent/CN111192634A/zh active Pending
- 2012-01-19 JP JP2013549922A patent/JP6420543B2/ja not_active Expired - Fee Related
- 2012-01-19 EP EP12704126.7A patent/EP2666115A1/en not_active Withdrawn
- 2012-01-19 BR BR112013018139A patent/BR112013018139A8/pt not_active IP Right Cessation
- 2012-01-19 WO PCT/IB2012/050255 patent/WO2012098515A1/en not_active Ceased
- 2012-01-19 RU RU2013138422/10A patent/RU2013138422A/ru not_active Application Discontinuation
- 2012-01-19 CN CN2012800059273A patent/CN103329138A/zh active Pending
- 2012-01-19 US US13/979,908 patent/US20140229495A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009108802A2 (en) * | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
Non-Patent Citations (1)
| Title |
|---|
| MARC A. BOLLET等: "High-Resolution Mapping of DNA Breakpoints to Define True Recurrences Among Ipsilateral Breast Cancers" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119541627A (zh) * | 2025-01-22 | 2025-02-28 | 温州医科大学附属眼视光医院 | 一种在基因转录水平评价蛋白质结合效率的方法、设备、介质和程序产品 |
| CN120496715A (zh) * | 2025-05-23 | 2025-08-15 | 康奥生物科技(天津)股份有限公司 | 一种试验遴选研究方法及系统 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013138422A (ru) | 2015-02-27 |
| JP2014508994A (ja) | 2014-04-10 |
| WO2012098515A1 (en) | 2012-07-26 |
| CN103329138A (zh) | 2013-09-25 |
| US20140229495A1 (en) | 2014-08-14 |
| BR112013018139A2 (pt) | 2016-11-08 |
| JP6420543B2 (ja) | 2018-11-07 |
| BR112013018139A8 (pt) | 2018-02-06 |
| EP2666115A1 (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111192634A (zh) | 用于处理基因组数据的方法 | |
| US20230187070A1 (en) | Systems and methods for multi-label cancer classification | |
| US20250364135A1 (en) | Systems and methods for multi-label cancer classification | |
| JP7458360B2 (ja) | 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法 | |
| JP7487163B2 (ja) | がんの進化の検出および診断 | |
| AU2019229273B2 (en) | Ultra-sensitive detection of circulating tumor DNA through genome-wide integration | |
| EP4073805B1 (en) | Systems and methods for predicting homologous recombination deficiency status of a specimen | |
| JP2024016039A (ja) | 相同組換え欠損を推定するための統合された機械学習フレームワーク | |
| US20220367010A1 (en) | Molecular response and progression detection from circulating cell free dna | |
| JP2014508994A5 (https=) | ||
| US20140040264A1 (en) | Method for estimation of information flow in biological networks | |
| CA3204451A1 (en) | Systems and methods for joint low-coverage whole genome sequencing and whole exome sequencing inference of copy number variation for clinical diagnostics | |
| US20190228836A1 (en) | Systems and methods for predicting genetic diseases | |
| JP2025158958A (ja) | 腫瘍情報に基づいた循環腫瘍割合の推定のための方法およびシステム | |
| JP2025124606A (ja) | 液体生検アッセイにおける血液腫瘍遺伝子変異量を決定するための方法およびシステム | |
| WO2025122662A1 (en) | Systems and methods for detecting somatic variants derived from circulating tumor nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200522 |